Billionaire Andreas Halvorsen’s Top 15 Long-Term Stock Picks

Page 9 of 15

7. Roivant Sciences Ltd. (NASDAQ:ROIV)

Number of Hedge Fund Holders: 50

Viking Global’s Stake: $624.3 million  

Roivant Sciences Ltd. (NASDAQ:ROIV) is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. These key points underline why the company is a sound investment decision. To begin with, as the report of the third quarter of 2024 suggests, the company has completed the sale of Telavant to Roche for $7.1 billion with an additional $150 million in cash payable upon the completion of a near-term milestone. Secondly, the company has agreed to sell an aggregate of 22,500,000 shares of common stock at a purchase price of $20 per share to three institutional accredited investors in a private investment in public equity (PIPE). Immunovant anticipates receiving aggregate gross proceeds of approximately $450 million from the PIPE, which may attract investors. Moreover, the company has launched a new pipeline program, Mosliciguat, a potential first-in-class and best-in-category inhaled once-daily Soluble Guanylate Cyclase (sGC) activator.

Page 9 of 15